Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [901]
News [1778]
Articles [228]
Editorials [5]
Conferences [136]
elearning [18]
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...
Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...
Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )
25 Oct 2018
Cardiac events in stage III NSCLC treated in daily clinical practice
Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )
25 Oct 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy
Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )
24 Oct 2018
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for...
Dr Maria Vittoria Dieci - University of Padua, Padova, Italy
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer ( Dr Maria Vittoria Dieci - University of Padua, Padova, Italy )
24 Oct 2018
Liquid biopsy as a monitoring tool for the benefit of chemotherapy...
Dr Laura Bonanno - University of Padova, Padova, Italy
Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC ( Dr Laura Bonanno - University of Padova, Padova, Italy )
24 Oct 2018
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer
Dr Chris C. Parker - The Royal Marsden, London, UK
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer ( Dr Chris C. Parker - The Royal Marsden, London, UK )
22 Oct 2018
Comment: Radiotherapy as a treatment option for metastatic prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Radiotherapy as a treatment option for metastatic prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
21 Oct 2018
Survival results from STAMPEDE, radiotherapy for prostate cancer
Dr Chris C. Parker - The Royal Marsden, London, UK
Survival results from STAMPEDE, radiotherapy for prostate cancer ( Dr Chris C. Parker - The Royal Marsden, London, UK )
21 Oct 2018
Novel therapies for paediatric B-ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Novel therapies for paediatric B-ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
18 Oct 2018
Can we reduce the intensity of frontline therapy?
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Can we reduce the intensity of frontline therapy? ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
18 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation